Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer.
about
Cytotoxic and targeted therapy for hereditary cancersThe biological effects and clinical implications of BRCA mutations: where do we go from here?Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancerHomologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian CancerGenomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancersTBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast CancerPARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directionsUse of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinicClinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C statusTriple-negative breast cancer: challenges and opportunities of a heterogeneous disease.Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes.Landscape of somatic mutations in 560 breast cancer whole-genome sequences.Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.A genomic instability score in discriminating nonequivalent outcomes of BRCA1/2 mutations and in predicting outcomes of ovarian cancer treated with platinum-based chemotherapyMultigene prognostic tests in breast cancer: past, present, futureAssociation of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105Massive interstitial copy-neutral loss-of-heterozygosity as evidence for cancer being a disease of the DNA-damage response.Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast Cancers.BRCA 1/2 gene mutation and gastrointestinal stromal tumours: a potential associationPoly (ADP-ribose) polymerase inhibitors: recent advances and future development.TP53 mutations, tetraploidy and homologous recombination repair defects in early stage high-grade serous ovarian cancer[The clonal evolution of osteosarcomas].BRCAness as a Biomarker for Predicting Prognosis and Response to Anthracycline-Based Adjuvant Chemotherapy for Patients with Triple-Negative Breast CancerExome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiencyFirst description of a sporadic breast cancer in a woman with BRCA1 germline mutation.Predictive significance of DNA damage and repair biomarkers in triple-negative breast cancer patients treated with neoadjuvant chemotherapy: An exploratory analysis.When Genome Maintenance Goes Badly Awry.Copy number deletion of RAD50 as predictive marker of BRCAness and PARP inhibitor response in BRCA wild type ovarian cancer.Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy.Loss of BRCA1 or BRCA2 markedly increases the rate of base substitution mutagenesis and has distinct effects on genomic deletions.Pathogenesis and heterogeneity of ovarian cancer.BRCA 1/2-Mutation Related and Sporadic Breast and Ovarian Cancers: More Alike than Different.PARP Inhibitors in Reproductive System Cancers: Current Use and Developments.Homology-directed repair of DNA nicks via pathways distinct from canonical double-strand break repair.Homologous recombination deficiency (HRD) testing in ovarian cancer clinical practice: a review of the literature.Triple-negative breast cancer: bridging the gap from cancer genomics to predictive biomarkers.The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast CancerIn vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma.Molecular pathogenesis of B-cell posttransplant lymphoproliferative disorder: what do we know so far?
P2860
Q26739366-85C74DEE-B1C4-4A00-A42B-D477FAF8349FQ26741851-8AB35E9A-C2A1-4C63-97A7-9A6149336110Q26780387-531289A0-B7F7-4D9F-B83C-8E70DA672F1BQ26783551-A811F39A-1CE9-4981-AD40-2B1B0D2C1FE1Q27006938-4C80BFB6-CE35-4974-A950-8BBF177E715DQ27853147-3C7EE40D-E5D0-44DE-A331-3E7B2F1DF3EDQ28071345-7910A042-1F48-417E-ABBE-765639F76F64Q28071541-6E3D96A6-0142-44F8-B5EE-012230DF20CDQ28307436-803876A1-6F4F-46EA-B8E9-CC4FF86544E3Q33769821-C088CBC0-1BC4-4C6C-BB1D-4C6D4257FCCDQ33874621-248FFEF0-D19F-493B-9D13-538F77600480Q34046731-5DD2FE37-EEE5-4BD2-814B-08CB887B2DAEQ34520145-C1430A1A-5BEC-4FBA-B67C-326558B237CDQ34599539-5046DD0B-E335-43A6-AD07-DC9EA801EF37Q35018599-AA634953-8109-46C4-A015-D340ADDBF7D8Q35021314-1F165BDA-77B2-42CE-B8BE-0ED831AF8F71Q35671356-909FFA47-D71D-4326-964B-72302A984F90Q35712405-9D94670B-D5A5-402B-95C5-5D94806B6170Q35812762-61F443C0-070B-4F42-982F-A7A9D4377686Q35823594-E32C45B0-0121-41F0-BBB9-995C024462EBQ35895214-A8E27CD7-8F2D-4276-8AE0-3ECA2A706B5FQ35961836-4E0D0068-F308-42A9-B2F6-7EC2B3B98F43Q36139023-41C54E3A-64C9-4E05-A4B8-EDB5BD30C2E6Q36224769-63E4E8EA-CC4C-4EB8-ACC7-24B55F49BFC3Q36392466-00A6AEC2-F808-431F-8714-6C9BA5E72E29Q36546414-8E34C485-3435-4628-8BFD-1CFF814D9166Q36619000-7A69180A-2A94-47EC-A9D0-A5875B4F4132Q37138583-68EAAE04-C41A-4396-B842-F0DCFFC502DAQ37140001-0CFDF08F-E731-4592-B099-3DC8BE1998B8Q37158437-79BFCD94-B7E7-49FA-8776-D2CCE5ECBF2AQ37395490-738CC9AF-FC79-4838-9DB9-12F6D3858FF6Q37546692-78062302-24FE-4592-8B51-93B1785F204AQ37605747-9B7C6EB6-08AC-4B30-AD48-1EFEC6F68728Q37607283-EB3E65DB-F7DB-48B7-A601-7D470AC0DF9AQ37640986-25AD0DB4-93E5-41DF-9696-DAF2EDB35C3AQ37661436-F1A8E2F7-DC12-4A50-8E3B-10EFA5E7A1E0Q37704344-372C70EC-5F3B-40EA-8CC3-724240139A64Q37720246-D110E980-618D-4760-8929-E9E065115BEBQ37726508-39F774D6-20B5-4CB8-A5E3-A7DDBD900F42Q38108302-8CCCCEC7-C1E4-4BD3-B230-CBD95668EA26
P2860
Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Patterns of genomic loss of he ...... in epithelial ovarian cancer.
@ast
Patterns of genomic loss of he ...... in epithelial ovarian cancer.
@en
type
label
Patterns of genomic loss of he ...... in epithelial ovarian cancer.
@ast
Patterns of genomic loss of he ...... in epithelial ovarian cancer.
@en
prefLabel
Patterns of genomic loss of he ...... in epithelial ovarian cancer.
@ast
Patterns of genomic loss of he ...... in epithelial ovarian cancer.
@en
P2093
P2860
P356
P1476
Patterns of genomic loss of he ...... in epithelial ovarian cancer.
@en
P2093
B T Hennessy
D Williams
J A DeLoia
J S Lanchbury
P2860
P2888
P304
P356
10.1038/BJC.2012.451
P407
P577
2012-10-09T00:00:00Z